Article Text

Download PDFPDF
Brain aneurysm and parent vessel remodeling after flow diversion treatment: a proposed modification for Cekirge-Saatci classification (mCSC)

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Twitter @cure4stroke

  • Contributors All authors have substantially contributed to the conception and design of the study. RAH: contributed to data interpretation, planning, conception and design, manuscript preparation. GMC: contributed to data interpretation, conception and design, manuscript preparation. DKL: contributed to data interpretation, planning, conception and design, manuscript preparation. IS: contributed to data interpretation, planning, conception and design, manuscript preparation. HSC: contributed to data interpretation, planning, conception and design, manuscript preparation.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests RAH is a consultant for Medtronic, Stryker, Cerenovous, Microvention, Balt, Phenox, Rapid Medical, and Q'Apel. He is on the advisory board for MiVI, eLum, Three Rivers, Shape Medical and Corindus. Unrestricted research grant from NIH, Interline Endowment, Microvention, Stryker, CNX. Investor/stockholder for InNeuroCo, Cerebrotech, eLum, Endostream, Three Rivers Medical Inc, Scientia, RisT, BlinkTBI, and Corindus. Unrestricted research grant from NIH, Interline Endowment, Microvention, Stryker, CNX. Investor/stockholder for InNeuroCo, Cerebrotech, eLum, Endostream, Three Rivers Medical Inc, Scientia, RisT, BlinkTBI, and Corindus. GMC has no disclosures to report. DKL is consultant for Medtronic, Stryker, Asahi, Rapid.AI and QApel. Advisory Board: Q’Apel, Siemens, investor/stockholder for Three Rivers, Q’Apel, Vastrax, Synchron, Viz.AI, Methinks, Bendit, eLum, NVI. IS is a consultant and has proctorship agreements with Medtronic and MicroVention Inc. HSC is a consultant and has proctorship agreements with Medtronic and MicroVention Inc. Shareholder of Neuravention, Sychron Inc, Bend It Tech, Sim & Cure and Vesalio LLC.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.